Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
- Monica M. Mita
- , Alain C. Mita
- , Jennifer L. Moseley
- , Jennifer Poon
- , Karen A. Small
- , Ying Ming Jou
- , Paul Kirschmeier
- , Da Zhang
- , Yali Zhu
- , Paul Statkevich
- , Kamelesh K. Sankhala
- , John Sarantopoulos
- , James M. Cleary
- , Lucian R. Chirieac
- , Scott J. Rodig
- , Rajat Bannerji
- , Geoffrey I. Shapiro
Research output: Contribution to journal › Article › peer-review
52
Link opens in a new tab
Scopus
citations